Drug updated on 3/28/2024
Dosage Form | Capsules (oral: 100 mg, 200 mg, 300 mg) |
Drug Class | Unknown mechanism of action |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of orthostatic dizziness and light-headedness or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropath
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Northera (droxidopa) Prescribing Information. | 2019 | Lundbeck, Deerfield, IL |